...Yeah. Just overall, before we dive into the deeper questions, just wanted to say that we've had a great start to the year and looking forward to closing strong. Everything that we set out to do in our guidance we've accomplished. On our 201 lead gene therapy program for the leading genetic cause of HCM, we successfully dosed the high-dose cohort, successfully got the DSMB clearance, and which is important from a safety perspective. We've released data from our natural history study, which is the largest natural history study in the world for this disease, for the children with this mutation, very severe disease. And then we're on track to deliver data in the second half of this year. We had first narrowed our guidance to Q4, but we're happy to share today breaking news at the Morgan Stanley Healthcare Conference that as of 2 PM Eastern today we're able to share that we were accepted for a late-breaker clinical presentation in the main conference at the American Heart Association, happen...
